Teja Kapoor

Rheumatologist

[Teja Kapoor @TejaKapoor]

Excited to share Sjögren’s Calculator, a free clinician-facing tool to support standardized ESSDAI calculation and documentation in routine care.
🔗 https://t.co/mMQABNKtea
Future goals include ClinESSDAI, ESSPRI, and other Sjögren’s assessment tools. #ESSDAI #Sjögrens

[Teja Kapoor @TejaKapoor]

Decoding Sjogren’s Disease: A Clinical Deep Dive @iHeartRadio https://t.co/dCTPjdQjln

[Teja Kapoor @TejaKapoor]

Join us for our ‘#CardioRheumatology Symposium: Inflammatory Cardiac & #CardiovascularDisease' - a virtual and in-person program on Friday, May 30, 2025. 7.25 ACCME Credits. https://t.co/PjEz8Kv7qH
#Myocarditis #Rheumatology #Cardiology#Immunotherapy

[Teja Kapoor @TejaKapoor]

#ACR19

[Teja Kapoor @TejaKapoor]

Effect of immunosuppressants on Flu and Pneumococcal vaccines #ACR2019

[Teja Kapoor @TejaKapoor]

Effect of immunosuppressants on Flu and Pneumococcal vaccines #ACR2019

[Jilaine Bolek Berquist @BolekBerqui]

Steroid dose >10mg /day is biggest risk of infection (13% increased risk) during elective joint replacement in RA. Bigger than biologic therapy. #ACR19

[Dr. John Cush @RheumNow]

Wk in Review is up! Dr Cush reviews new approvals, defensins,Cost of T2T; Listen to podcast https://t.co/qNge5gwhQE https://t.co/WDy2oVlVV8

[Teja Kapoor @TejaKapoor]

In Lupus, need to weigh risk vs benefit of PCP prophylaxis.Bactrim may cause allergy rxn or SLE flare & PCP prevalence is very low in SLE https://t.co/6SICourAYV

[EMR Research papers @EMR_research]

Low prevalence of Pneumocystis pneumonia in hospitalized patients with systemic lupus erythematosus: review of a… https://t.co/4BZWumQNTO

[Teja Kapoor @TejaKapoor]

If you had patient with gout not yet at target, when would u prefer to add lesinurad rather than switch to febuxostat? #RheumJC

[Teja Kapoor @TejaKapoor]

On epocrates it mentions CV event risk as a serious adverse event with lesinurad, what type of events did they find? #rheumjc

[Teja Kapoor @TejaKapoor]

No coi #rheumjc

[Teja Kapoor @TejaKapoor]

Hello, Teja Kapoor here from Columbia univ #rheumjc

[Teja Kapoor @TejaKapoor]

#rheumjc. in France, have there been any patient instances where you've used triple therapy

[Teja Kapoor @TejaKapoor]

#rheumjc hello this is Dr. Kapoor from Columbia

[Annals of the Rheumatic Diseases @eular_ARD]

Identification of human CD3+ CD20+ T cells- implications for #Rituximab use? #immunology #rheumedu https://t.co/zWNIrHC0Oc

[Rheumatology Update @rheumaupdate]

Tocilizumab offers hope in GCA | Rheumatology Update: https://t.co/WLHXQi16O3